TTAC-0001 and Pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer
Condition(s):Triple Negative Breast CancerLast Updated:August 17, 2022Active, not recruiting
Hide Studies Not Open or Pending
Condition(s):Triple Negative Breast CancerLast Updated:August 17, 2022Active, not recruiting
Condition(s):Triple Negative Breast CancerLast Updated:November 17, 2022Withdrawn
Condition(s):Triple Negative Breast Cancer; Residual DiseaseLast Updated:October 28, 2021Recruiting
Condition(s):Stage 1 cT1b-T1cN0M0; Triple Negative Breast CancerLast Updated:March 19, 2024Not yet recruiting
Condition(s):Triple Negative Breast CancerLast Updated:November 22, 2023Active, not recruiting
Condition(s):Triple Negative Breast CancerLast Updated:October 27, 2020Terminated
Condition(s):Triple-Negative Breast CancerLast Updated:November 30, 2020Terminated
Condition(s):Triple Negative Breast CancerLast Updated:June 1, 2018Withdrawn
Condition(s):Triple Negative Breast CancerLast Updated:November 24, 2021Unknown status
Condition(s):Metastatic Triple Negative Breast Cancer; Metastatic Colorectal CancerLast Updated:February 20, 2024Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.